Effect of pre- and post-surgical active BCG immunotherapies on murien EAkR lymphosarcoma.
A combined treatment modality incorporating surgery plus BCG immunotherapy was administered to (DBA/2 X C57B/6) F1 mice grafted with EAkR lymphosarcoma. 30% of mice survived free of disease when BCG was injected intravenously two days after operation consisting of tumorectomy plus excision of the regional lymph node performed on the 8th day after tumor inoculation. Similar results were obtained when BCG was injected subcutaneously 6 days before surgery. Pre-operative intravenous and post-operative subcutanous BCG administration failed to cure the animals just as BCG or surgery alone.
D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use*; D005260:Female; D008197:Lymph Node Excision; D008228:Lymphoma, Non-Hodgkin / Q000601:surgery / Q000628:therapy*; D051379:Mice; D012513:Sarcoma, Experimental; D013997:Time Factors
D001500:BCG Vaccine